Adma Biologics Stock Today
| ADMA Stock | USD 21.30 0.07 0.33% |
Performance5 of 100
| Odds Of DistressLess than 8
|
ADMA Biologics is trading at 21.30 as of the 21st of November 2024, a 0.33 percent decrease since the beginning of the trading day. The stock's open price was 21.37. ADMA Biologics has only a 8 % chance of going through financial distress over the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for ADMA Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of October 2013 | Category Healthcare | Classification Health Care |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. The company has 236.39 M outstanding shares of which 15.2 M shares are presently shorted by private and institutional investors with about 3.53 trading days to cover. More on ADMA Biologics
Moving against ADMA Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ADMA Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Adam Grossman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsADMA Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ADMA Biologics' financial leverage. It provides some insight into what part of ADMA Biologics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADMA Biologics (ADMA) is traded on NASDAQ Exchange in USA. It is located in 465 State Route 17, Ramsey, NJ, United States, 07446 and employs 624 people. ADMA Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.05 B. ADMA Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 236.39 M outstanding shares of which 15.2 M shares are presently shorted by private and institutional investors with about 3.53 trading days to cover.
ADMA Biologics currently holds about 52.42 M in cash with 8.8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check ADMA Biologics Probability Of Bankruptcy
Ownership AllocationADMA Biologics holds a total of 236.39 Million outstanding shares. The majority of ADMA Biologics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ADMA Biologics to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in ADMA Biologics. Please pay attention to any change in the institutional holdings of ADMA Biologics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ADMA Ownership Details
ADMA Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Investments Llc | 2024-06-30 | 4 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 4 M | |
| Magnetar Financial Llc | 2024-06-30 | 3.7 M | |
| Renaissance Technologies Corp | 2024-09-30 | 3.7 M | |
| Assenagon Asset Management Sa | 2024-09-30 | 3.5 M | |
| Deutsche Bank Ag | 2024-06-30 | 3 M | |
| Driehaus Capital Management Llc | 2024-06-30 | 3 M | |
| Northern Trust Corp | 2024-09-30 | 2.4 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 2.4 M | |
| Blackrock Inc | 2024-06-30 | 18.6 M | |
| Vanguard Group Inc | 2024-09-30 | 18.1 M |
ADMA Biologics Historical Income Statement
ADMA Stock Against Markets
ADMA Biologics Corporate Management
| CPA CPA | CFO VP | Profile | |
| Michael Goldstein | Sr Counsel | Profile | |
| Neal Fitzpatrick | Vice Sales | Profile | |
| Kaitlin Kestenberg | Project Compliance | Profile | |
| Cyndi Tolman | VP Services | Profile | |
| Dr DPS | CoFounder Chairman | Profile |
Already Invested in ADMA Biologics?
The danger of trading ADMA Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADMA Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADMA Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADMA Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.28 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.